Evidence for the formation of amphotericin B-phospholipid complexes in Langmuir monolayers

Pharmaceutical Research

Volumn 13, Issue 7, 1996, Pages 1008-1014

  Lance, Martin R ^a   Washington, Clive ^b   Davis, Stanley S ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NONE

Author keywords

Amphotericin B; Emulsion; Lecithin; Low dimensional structures; Monolayer; Stability

Indexed keywords

AMPHOTERICIN B; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; LIPID EMULSION; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID;

ARTICLE; COMPRESSION; DRUG FORMULATION; DRUG STABILITY; ENCAPSULATION; LIGHT SCATTERING; PHASE TRANSITION; PRIORITY JOURNAL;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DRUG CARRIERS; EMULSIONS; MEMBRANES, ARTIFICIAL; PHOSPHATIDYLCHOLINES; SURFACE PROPERTIES;

EID: 0029738181     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016046321726     Document Type: Article

References (28)

1. H. A. Gallis, R. H. Drew, and W. W. Pickard. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:308-329 (1990).
2. P. D. Hoeprich. Clinical use of amphotericin B and derivatives: lore, mystique, and fact. J. Clin. Infect. Dis. 14 (Suppl. 1), S114-S119 (1992).
3. M. A. Carlson and R. E. Condon. Nephrotoxicity of amphotericin B. J. Amer. Coll. Surg. 179:361-381 (1994).
4. J. P. Adler-Moore and R. T. Proffitt. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J. Lipos. Res. 3:429-450 (1993).
5. L. S. S. Guo and P. K. Working. Complexes of amphotericin B and cholesteryl sulfate. J. Lipos. Res. 3:473-490 (1993).
6. A. S. Janoff, W. R. Perkins, S. L. Saletan, and C. E. Swenson. Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B related toxicities. J. Lipos. Res. 3:451-471 (1993).
7. R. C. C. New. Antileishmanial activity of ampholericin and other antifungal agents entrapped in liposomes. J. Antimicrob. Chemother. 8:371-381 (1981).
8. N. I. Payne, R. F. Cosgrove, A. P. Green, and L. Liu. Formulation aspects of proliposomes: in-vivo studies of liposomes containing amphotericin B. Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 12:276-277 (1985).
9. N. I. Payne, R. F. Cosgrove, A. P. Green, and L. Liu. In-vivo studies of amphotericin B liposomes derived from proliposomes: effect of formulation on toxicity and tissue distribution of the drug in mice. J. Pharm. Pharmacol. 39:24-28 (1987).
10. R. L. Juliano, C. W. M. Grant, K. R. Barber, and M. P. Kalp. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol. Pharmacol. 31:1-11 (1987).
11. F.C. Szoka, D. Milholland, and M. Barza. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob. Agents Chemother. 31:421-429 (1987).
12. V. Joly, J. Bolard, L. Saint-Julien, C. Carbon, andP. Yeni. Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipidassociated amphotericin B formulations. Antimicrob. Agents Chemother. 36:262-266 (1992).
13. C. Washington and S. S. Davis. Nottingham University European Patent Application No. 90913513.9 (1991).
14. C. Washington, S. J. Taylor, and S. S. Davis. The structure of colloidal formulations of amphotericin B. Int. J. Pharm. 46:25-30 (1988).
15. D. Forster, C. Washington, and S. S. Davis. Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes. Pharm. Pharmacol. 40:325-328 (1988).
16. M. R. Lance, C. Washington, and S. S. Davis. Structure and toxicity of amphotericin B/triglyceride emulsion formulations. J. Antimicrob. Chemother. 36:119-128 (1995).
17. K. A. Lamb, C. Washington, S. S. Davis, and S. P. Denyer. Toxicity of amphotericin B emulsion to cultured canine kidney cell monolayers. J. Pharm. Pharmacol. 43:522-524 (1991).
18. C. Washington, O. Lutz, and S. S. Davis. Stability of an amphotericin B emulsion formulation. J. Pharm. Pharmacol. 43:93P (1991).
19. C. Washington and S. S. Davis. The production of parenteral feeding emulsions by Microfluidizer. Int. J. Pharm. 44:169-176 (1988).
20. C. Washington. The stability of intravenous fat emulsions in total parenteral nutrition mixtures. Int. J. Pharm. 66:1-21 (1990).
21. R. A. Hann. Molecular structure and monolayer properties. In G. Roberts (Ed.), Langmuir-Blodgett films, Plenum Press, New York, 1990, pp. 19-20.
22. H. E. Ries, M. Matsumoto, N. Uyeda, and E. Suito. Electron micrographs of cholesterol monolayers. J. Colloid. Interface Sci. 57:396-398 (1976).
23. O. Albrecht, H. Gruler, and E. Sackmann. Polymorphism of phospholipid monolayers. J. Phys. (Paris) 39:301-313 (1978).
24. M. E. Losche, E. Sackmann, and H. Mohwald. A fluorescence microscopic study concerning the phase diagram of phospholipids. Ber. Bunsenges. Phys. Chem. 87:848-852 (1983).
25. R. Peters and K. Beck. Translational diffusion in phospholipid monolayers measured by fluorescence microphotolysis. Proc. Nat. Acad. Sci. USA 80:7183-7187 (1983).
26. H. M. McConnell, L. K. Tamm, and R. M. Weis. Periodic structures in lipid monolayer phase transitions. Proc. Nat. Acad. Sci. USA 81:3249-3253 (1984).
27. L. K. Tamm, and H. M. McConnell. Supported phospholipid bilayers. Biophys. J. 47:105-113 (1985).
28. S. Benita and M. Y. Levy. Submicron emulsions as colloidal drug carriers for intravenous administration: comprehensive physicochemical characterisation. J. Pharm. Sci. 82:1069-1079 (1993).